



High-Flow or Standard Oxygen?

Key Article

- Frat JP, et al. High-flow or standard oxygen in acute hypoxemic respiratory failure. *N Engl J Med.* 2026; published online March 17, 2026.

Background

- Acute respiratory failure is the leading cause of admission to the ICU.
- Acute hypoxemic respiratory failure in the absence of cardiogenic pulmonary edema or chronic respiratory diseases is primarily caused by viral or bacterial pneumonia.
- O₂ is the first-line therapy for acute hypoxemic respiratory failure and can be given with a standard NRB mask, with high-flow through a nasal cannula, or with NIV.
- The primary goal of managing acute hypoxemic respiratory failure is to avoid intubation.
- Standard O₂ is limited in its ability to provide high levels of FiO₂ and to unload respiratory effort.
- In contrast, high-flow oxygen and NIV improve oxygenation and relieve patient effort and dyspnea.
- Current guidelines recommend the use of high-flow oxygen rather than NIV or standard oxygen as first-line for acute hypoxemic respiratory failure with respect to a reduced risk of intubation, although results on mortality are less consistent.
- To address the lack of evidence on whether high-flow is superior to standard oxygen in reducing mortality, these authors conducted the SOHO Trial...

Objective

- To compare two oxygenation strategies (high flow vs. standard O₂) in patients who were admitted to an ICU for acute hypoxemic respiratory failure.

Methods

- Investigator-initiated, open-label, RCT
- 42 ICUs in France
- Patients - Included
 - Adults greater than or equal to 18 years of age
 - Admitted to the ICU with acute hypoxemic respiratory failure
 - RR > 25 bpm
 - Pulmonary infiltrates on CXR
 - P/F of 200 or less while breathing O₂ at 10 L/min through a NRB
- Patients – Excluded
 - PaCO₂ > 45 mm Hg
 - COPD exacerbation
 - Chronic lung disease with long-term O₂
 - Cardiogenic pulmonary edema
 - Hemodynamically unstable

- Altered mental status
- Need for emergent intubation
- DNR
- Randomization
 - Within the first 3 hours of meeting inclusion criteria
 - 1:1 to High-Flow Group or Standard Oxygen Group
 - High-Flow Group
 - Flow rate of at least 50 L/min
 - FiO₂ adjusted to maintain SpO₂ 92-96%
 - Provided for at least 48 hours
 - After 48 hours, could be stopped and switched to standard O₂ if the RR < 25 bpm and SpO₂ of at least 92% with an FiO₂ of 40% or less
 - Standard Oxygen Group
 - O₂ delivered through a NRB with O₂ set at 10 L/min or more
 - Adjusted to maintain an SpO₂ 92-96%
- Primary Outcomes
 - 28-day all-cause mortality
- Secondary Outcomes
 - Endotracheal intubation at day 28
 - Interval between randomization and intubation
 - Ventilator free days
 - ICU mortality, in-hospital mortality, 90-day mortality
 - ICU and hospital LOS
- To ensure consistency of intubation, investigators developed specified criteria
 - Severe respiratory failure
 - RR > 40 bpm
 - Respiratory muscle fatigue
 - pH < 7.35
 - P/F < 100 mm Hg despite 15 L/min
 - FiO₂ of 80% or more
 - Recurrent episodes of SpO₂ < 80%
 - SpO₂ < 88% with maximal O₂ support
 - Cardiac arrest
 - Hemodynamic instability
 - Deterioration of neurologic status
- Statistical Analysis
 - Calculated sample size of 1110 patients to provide 80% to show an absolute difference of 6% points in 28-day mortality

Results

- A total of 1,110 included in the ITT analysis
 - High-Flow Group: 556 patients
 - Standard Group: 554 patients
- Baseline characteristics
 - Well balanced except High-Flow Group had a higher % of men, higher median dyspnea score, and lower RR than Standard Group
 - Pneumonia was the leading cause of respiratory failure – 88%

- Viral pneumonia in 53%
 - COVID-19 in 32%
- Interventions
 - High-Flow Group
 - Initial flow: 51 L/min
 - FiO₂: 67%
 - Standard Group
 - Initial flow: 12 L/min
 - Both high-flow and standard O₂ were delivered for a median of 4 days
 - NIV applied as rescue in 37 patients
- Primary Outcome
 - High-Flow Group: 14.6%
 - Standard Group: 14.6%
- Secondary Outcomes
 - Incidence of intubation at day 28
 - High-Flow Group: 42.4%
 - Standard Group: 48.4%
 - CI -11.78 to -0.08
 - High-Flow appeared to improve RR, CO₂ values, and dyspnea scores
- Safety Outcomes
 - Pneumothorax
 - High-Flow Group: 10
 - Standard Group: 4
 - Cardiac Arrest
 - High-Flow Group: 3
 - Standard Group: 2

Limitations Identified by Authors

- Overall lower than expected mortality rate, which reduced the statistical power – could be due to the frequent use of steroids (62%)
- Trial did not have a DSMB
- High percentage of patients with viral pneumonia

Take Home Points

- The use of high-flow oxygen did not lower 28-day all-cause mortality in adult patients admitted to the ICU with acute hypoxemic respiratory failure.